OncoCyte (NASDAQ:OCX) Announces Earnings Results

OncoCyte (NASDAQ:OCX) released its earnings results on Monday. The company reported $0.48 EPS for the quarter, Zacks reports. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%.

OncoCyte Stock Down 2.1 %

NASDAQ:OCX traded down $0.07 on Monday, reaching $3.33. 32,727 shares of the stock traded hands, compared to its average volume of 65,649. OncoCyte has a 12 month low of $1.92 and a 12 month high of $4.75. The company’s fifty day simple moving average is $2.68 and its 200 day simple moving average is $2.72.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of OncoCyte in a research report on Monday, January 13th. They set a “sell” rating on the stock.

Insider Activity

In other OncoCyte news, Director Andrew Arno bought 12,500 shares of OncoCyte stock in a transaction on Thursday, December 26th. The stock was acquired at an average cost of $2.11 per share, with a total value of $26,375.00. Following the completion of the acquisition, the director now owns 81,554 shares in the company, valued at approximately $172,078.94. This represents a 18.10 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Patrick W. Smith purchased 90,219 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was acquired at an average price of $2.13 per share, for a total transaction of $192,166.47. Following the completion of the transaction, the insider now directly owns 1,773,903 shares of the company’s stock, valued at approximately $3,778,413.39. This trade represents a 5.36 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,288,344 shares of company stock valued at $2,649,051 over the last ninety days. 1.58% of the stock is currently owned by corporate insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.